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Abstract: This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities
and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 “harvest” have
been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides;
amino acids and natural products; drug combinations; and small molecules.
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Taking the last 20 years as a reference, 2017 witnessed a record in terms of new entities approved
by the FDA: 34 New Chemical Entities (NCEs) (see Figure 1) and 12 biologics [1]. This number is close
to the peak reached in 1996, when 59 entities (53 NCEs and 6 biologics) were approved, and much
greater than the numbers achieved in recent years [1]. Furthermore, the numbers in 2017 represent
a breakthrough when compared with 2016, when only 22 (15 + 7) entities were approved. However,
and as occurred in the previous year, analysts interpret the 2017 figures with caution since the launch
of a new drug onto the market involves many variables that are difficult to predict [2,3].
The number of biologics approved (12) in 2017 implies the consolidation of this kind of drug.
This excellent number is further supported by the six approvals granted by the Center for Biologics
Evaluation and Research (CBER), including the first gene therapy treatment [2,4].
Of the 12 biologics approved in 2017, nine are antibodies, one is an antibody-drug conjugate
(ADC), and two are enzymes (Table 1).
It is important to draw attention to the approval of the ADC, BesponsaTM, for the treatment of
acute lymphoblastic leukemia. In 2016, no such compound was approved. Besponsa can be considered
a second generation of MylotargTM (gemtuzumab ozogamicin), which, in 2000, was the first ADC
approved by the FDA for the treatment of acute myeloid leukemia [5]. In 2010, MylotargTM was
withdrawn from the market because, when combined with chemotherapy, it did not enhance survival
and it showed greater toxicity than the chemotherapy alone. However, MylotargTM was approved
again by the FDA in September 2017 for the treatment of acute myeloid leukemia whose tumors
express the CD33 antigen. Analysts forecast that more ADCs will be approved by the FDA in the
coming years [6].
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Table 1. Biologics approved by the FDA in 2017 [1]. 
Active Ingredient Trade Name a Disease 
Avelumab BavencioTM b Merkel cell carcinoma 
Dupilumab DupixentTM b Asthma 
Benralizumab FasenraTM b Asthma 
Emicizumab HemlibraTM b Hemophilia A 
Durvalumab ImfinziTM b Urothelial carcinoma 
Sarilumab KevzaraTM b Rheumatoid arthritis 
Ocrelizumab OcrevusTM b Multiple sclerosis 
Brodaluma SiliqTM b Psoriasis 
Guselkumab TremfyaTM b Psoriasis 
Inotuzumab ozogamicin BesponsaTM c Acute lymphoblastic leukemia 
Cerliponase alfa DupixentTM d Batten disease 
Vestronidase alfa FasenraTM d Sly syndrome 
a USA; b antibody; c ADC; d enzyme. 
With regard to TIDES (oligonucleo- and pep-TIDES), while 2016 was an excellent year for 
oligonucleotides (three were approved) [7], 2017 was exceptional for peptides (six approved in 
comparison with one in 2016) (Figure 2). From a structural point of view, the six peptides cover almost 
the whole spectrum of complexity. Angiotensin II (GiaprezaTM) is a simple linear octapeptide for the 
control of blood pressure in adults with sepsis or other critical conditions. Etelcalcetide (ParsabivTM), 
for the treatment of secondary hyperparathyroidism, is an intriguing peptide formed by a chain of 
seven D-amino acids with an acetylated D-Cys at the N-terminal, which forms a disulfide bridge with 
a L-Cys, which is the only L-amino acid in the peptide. Plecanatide (TrulanceTM), formed by 16 amino 
acids and with two disulfide bridges, is indicated for the treatment of chronic idiopathic constipation. 
Plecanatide has a similar mode of action as Linaclotide (ConstellaTM-LinzessTM) (14 amino acids and 3 
disulfide bridges), already in the market [8]. Abaloparatide (TymlosTM) is a linear peptide comprising 
34 amino acids and contains an aminoisobutyric (Aib) residue. It is a parathyroid hormone-related 
protein analog for the treatment of osteoporosis. Semaglutide (OzempicTM) is a modified human 
glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes mellitus and it can be 
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Figure 1. New Chemical Entities and Biologics approved by the FDA in the last two decades [1,2].
Table 1. Biologics approved by the FDA in 2017 [1].
Active Ingredient Trade Name a Disease
Avelumab BavencioTM b Merkel cell carcinoma
Dupilumab DupixentTM b Asthma
Benralizumab FasenraTM b Asthma
Emicizumab HemlibraTM b Hemophilia A
Durvalumab I finziTM b Urothelial carcinoma
Sarilumab Kevzara b Rheumat id arthritis
Ocrelizumab OcrevusTM b Multiple sclerosis
Brodaluma SiliqTM b Psoriasis
Guselkumab TremfyaTM b Psoriasis
Inotuzumab ozogamicin BesponsaTM c Acute lymphoblastic leukemia
Cerliponase alfa Dupixent d Batten disease
Vestr nidase alfa FasenraTM d Sly s ndrome
a USA; b antibody; c ADC; d enzyme.
With regard to TIDES (oligonucleo- and pep-TIDES), while 2016 was an excellent year for
oligonucleotides (three were approved) [7], 2017 was exceptional for peptides (six approved in
comparison with one in 2016) (Figure 2). From a structural point of view, the six peptides cover almost
the whole spectrum of complexity. Angiotensin II (GiaprezaTM) is a simple linear octapeptide for the
control f blood pressure in adults with sepsis or other critical conditions. Etelc lcetide (ParsabivTM),
for the treatment of secondary hyperparathyroidism, is an intriguing peptide formed by a chain of
seven D-amino acids with an acet lated D-Cys at the N-termi al, which forms a disulfi e bridge with
a L-Cys, which is the only L-amino cid in the peptide. Plecanatide (TrulanceTM), forme by 16 amino
cids and wit two disulfide bridges, is i dicated for the tre tment of chronic idiopathic constipation.
Plecanatide has a similar mode of action as Linaclotide (ConstellaTM-LinzessTM) (14 amin acids and
3 disulfide bridges), already in the market [8]. Abal paratide (TymlosTM) is a linear peptide comprising
34 amino aci s and contains an a inoisobutyric (Aib) residue. It is a parathyroid hormone-related
protein an log for the treatme t of oste porosis. Semaglutide (Ozem icTM) is a m dified human
glucagon-like peptide-1 (GLP-1) anal g f r the treat ent of type 2 diabetes mellitus and it can be
administered once a week. Semaglutide is structurally similar to liraglutide, which was approved
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by the FDA in 2010, where the last residue before the N-terminal Ala is replaced by Aib and the acyl
moiety in the side-chain of the Lys contains two mini-PEG amino acids, one Glu residue linked to the
chain through theω-carboxylic group, and a C18 diacid.
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function. Betrixaban is indicated for the treatment of venous thromboembolism. Safinamide (XadagoTM), 
for Parkinson’s disease, is a derivative of the Ala (4-((3-fluorobenzyl)oxy)benzyl)-L-alaninamide. 
Netarsudil (RhopressaTM), for glaucoma, is a derivative of the β-amino acid (S)-3-amino-2-
phenylpropanoic acid, which is amidated with 6-amine-isoquinolin. Valbenazine (IngrezzaTM), used 
for tardive dyskinesia, is an ester of L-Val. 
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The ester part of valbenazine is found in one of the most intriguing drugs approved in 2017, 
namely Deutetrabenazine (AustedoTM) (Figure 4). Of note, this is the first deuterated drug ever 
approved by the FDA. Deutetrabenazine is the deuterated version (two deuterated methoxy groups) 
of a generic drug, tetrabenazine. The presence of deuterium is claimed to improve dosing properties 
and safety. Deutetrabenazine is indicated for chorea associated with Huntington’s disease. 
 
Figure 4. Structure of deutetrabenazine. 
Under the category of drugs inspired by natural products (Figure 5), ertugliflozin (SteglatroTM), 
for diabetes type 2, contains a core of glucose. Deflazacort (EmflazaTM), which is indicated for duchenne 
muscular dystrophy, is a glucocorticoid. Naldemedine (SymproicTM), a derivative of noroxymorphone, 
is used for opioid-induced constipation. 
 
Figure 5. Structure of drugs inspired by natural products. 
Interestingly, six drugs approved in 2017 contain the 2-amine-pyrimidine moiety (Figure 6). 
Ribociclib (KisqaliTM) for HR-positive/HER2-negative advanced or metastatic breast cancer; brigatinib 
(AlunbrigTM) for ALK-positive non-small-cell lung cancer; abemaciclib (VerzenioTM) for breast cancer; 
copanlisib (AliqopaTM) for follicular lymphoma; telotristat ethyl (XermeloTM) for carcinoid syndrome 
diarrhea; and letermovir (PrevymisTM) for the prevention of infection after bone marrow transplant. 
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The ester part of valbenazine is found in one of the most intriguing drugs approved in 2017,
namely Deutetrabenazine (AustedoTM) (Figure 4). Of note, this is the first deuterated drug ever
approved by the FDA. Deutetrabenazine is the deuterated version (two deuterated methoxy groups)
of a generic drug, tetrabenazine. The presence of deuterium is claimed to improve dosing properties
and safety. Deutetrabenazine is indicated for chorea associated with Huntington’s disease.
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Interestingly, six drugs approved in 2017 contain the 2-amin -pyrimidine moiety (Figure 6).
Ribociclib (KisqaliTM) for HR-positive/HER2-negative advanc d or metastatic breast cancer; brig tinib
(AlunbrigTM) for ALK-p sitive non-small-cell lung cancer; abemaciclib (VerzenioTM) for breast cancer;
copanlisib (AliqopaTM) for follicular lymphoma; telotristat ethyl (XermeloTM) for carcinoid syndrome
diarrhea; and letermovir (PrevymisTM) for the prevention of infection after bone marrow transplant.
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In 2016, two two-drug combinations for the treatment of hepatitis C, EpclusaTM and ZepatierTM 
were approved by the FDA. Both contain a hepatitis C virus NSSA inhibitor (velpatasvir and elbasvir, 
respectively) and sofosbuvir (nucleotide, viral RNA polymerase inhibitor) and grazopevir (macrocycle, 
NS3/4A protease inhibitor), respectively. In 2017, following the same trend for the treatment of the 
same disease, two more multi-drug combinations were also approved (Figure 8). Thus, VoseviTM adds a 
third drug, voxilaprevir, to the two present in EpclusaTM (velpatasvir and sofosbuvir). VoxilaprevirTM is a 
NS3/4A protease inhibitor. On the other hand, MavyretTM combines glecaprevir and pibrentasvir, 
which are NS3/4A and NS5A protease inhibitors, respectively. 
In 2017, one two-drug combination was approved for urinary infections (Figure 9). VabomereTM 
combines meropenem, a carbapenem-type antibiotic, and vaborbactam, a cyclic boronic acid 
pharmacophore that acts as a non-lactam–lactamase inhibitor. 
Two antibiotics based on the oxacin moiety (Figure 10), delafloxacin (BaxdelaTM), which is 
fluorinated, and ozenoxacin (XepiTM), which is non-fluorinated, were approved, thereby increasing 
the number of drugs in this family present on the market.  
Two drugs are a simple modification of a nitroimidazole moiety (Figure 11). Benznidazole 
(BenznidazoleTM), from 2-nitroimidazole, is for Chagas disease. Secnidazole (SolosecTM), for bacterial 
vaginosis, is derived from 5-nitroimidazole. Two more drugs contain a N-phenyl-pyrazole structure 
(Figure 12): niraparib (ZejulaTM) for fallopian tube, epithelial ovarian, or peritoneal cancer, and 
edaravone (RadicavaTM) for amyotrophic lateral sclerosis. 
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Enasidenib (IdhifaTM) is built on a triazine scaffold (Figure 7), which is also present in other drugs,
and is indicated for IDH2-positive acute myeloid leukemia.
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Figure 7. Structure of enasidenib that contains the triazine (in red) scaffold.
In 2016, two two-drug c for the treatment of hepatitis C, EpclusaTM and ZepatierTM
w re a proved by the FDA. Both co t i virus NSSA inhibitor (velpat svir and elbasvir,
respectively) and sofosbuvir (nucleotide, ir l l erase inhibitor) and grazopevir (macrocycle,
NS3/4A protease inhibitor), respectively. In 2017, follo ing the same trend for the treatment of the
same disease, two more multi-drug combinations were also approved (Figure 8). Thus, VoseviTM adds
a third drug, voxilaprevir, to the two present in EpclusaTM (velpatasvir and sofosbuvir). VoxilaprevirTM
is a NS3/4A protease inhibitor. On the other hand, MavyretTM combines glecaprevir and pibrentasvir,
which are NS3/4A and NS5A protease inhibitors, respectively.
In 2017, one two-drug combinatio was approved for urinary infections (Figure 9). VabomereTM
combines meropenem, a car apenem-type antibiotic, and vaborbactam, a cyclic boronic acid
pharmacophore that acts as a non-lactam–lactamase inhibitor.
Two antibiotics based on the oxacin moiety (Figure 10), delafloxacin (BaxdelaTM), which is
fluorinated, and ozenoxacin (XepiTM), which is non-fluorinated, were approved, thereby increasing
the number of drugs in this family present on the market.
Two drugs are a simple modification of a nitroimidazole moiety (Figure 11). Benznidazole
(BenznidazoleTM), from 2-nitroimidazole, is for Chagas disease. Secnidazole (SolosecTM), for bacterial
vaginosis, is derived from 5-nitroimidazole. Two more drugs contain a N-phenyl-pyrazole structure
(Figure 12): niraparib (ZejulaTM) for fallopian tube, epithelial ovarian, or peritoneal cancer, and edaravone
(RadicavaTM) for amyotrophic lateral scler sis.
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Finally, there are four more small-molecule drugs (Figure 13). The first three for distinct types 
of cancer: midostaurin (RydaptTM) for FLT3-positive acute myeloid leukemia; neratinib (NerlynxTM) 
for HER2-positive breast cancer; and acalabrutinib (CalquenceTM) for Mantle cell lymphoma and, 
finally, latanoprostene (VyzultaTM) for glaucoma-ocular hypertension. 
 
Figure 13. Structure of midostaurin, neratinib, acalabrutinib, and latanoprostene. 
As mentioned in the introduction, in “Drugs to the Market” it is very difficult to interpret trends 
and thus make forecasts for the coming years. However, if the approval of seven antibodies and three 
oligonucleotides were the most notable achievements in recent years, in 2017 the number of 
antibodies increased to nine and, more importantly, one ADC was approved. These figures serve to 
support the notion that these molecules will become the “Drugs of the Future” for the treatment of 
hitherto intractable diseases. It is to be hoped that production methods will evolve to be more cost 
effective and antibody-based drugs will become affordable for much of the population. This comment 
also applies to the production of combination drugs to treat hepatitis C, which are currently 
unaffordable for a large number of patients.  
The strength of the privileged structures in the drug discovery process has been clearly 
highlighted by the approval of six drugs containing 2-amine-pyrimidine moiety, one with a triazine 
structure, and two with a nitroimidazole.  
In 2017, the TIDES section was dominated by peptides. In this regard, six peptides ranging in 
size from small to large were approved. Five of them are produced using solid-phase technology, 
thereby showing once again that this simple but efficient approach developed by the Nobel Laureate 
Bruce Merrifield is a potent tool for drug discovery [10].  
Although cancer drugs received the most approvals in 2017, it is important to highlight that 
several drugs against infectious diseases were also authorized. 
The outputs from 2017 indicate that totally synthetic (from the idea) small molecules are losing 
ground against biologics, biomolecules, and other molecules inspired by natural products. However, 
all drugs, regardless of the chemical species involved, will be seen to achieve their mission if they are 
able to relieve suffering. There is hope that the figures for 2018 will exceed those of 2017.  
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, there are four more small-molecule drugs (Figure 13). The first three for dist nct types of
cancer: midostaurin (RydaptTM) for FLT3-positive acute myeloid leuk mia; neratinib (NerlynxTM) for
HER2-positive br ast c ncer; and acalabrutinib (CalquenceTM) for antle cell lymphoma and, finally
latanoprostene (VyzultaTM) for glaucoma-o ular hypertension.
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a ti o ies i crease  to i e a , ore i orta tl , o e  as a ro e . ese fi res ser e to 
s ort t e otio  t at t ese olec les ill eco e t e “ r s of t e t re” for t e treat e t of 
it erto i tracta le iseases. It is to e o e  t at ro ctio  et o s ill e ol e to e ore cost 
effecti e a  a ti o - ase  r s ill eco e affor a le for c  of t e o latio . is co e t 
also a lies to t e ro ctio  of co i atio  r s to treat e atitis , ic  are c rre tl  
affor a le for a lar e er of atie ts.  
e stre t  of t e ri ile e  str ct res i  t e r  isco er  rocess as ee  clearl  
i li te   t e a ro al of six r s co tai i  2-a i e- ri i i e oiet , o e it  a triazi e 
str ct re, a  t o it  a itroi i azole.  
I  2017, t e I S sectio  as o i ate   e ti es. I  t is re ar , six e ti es ra i  i  
size fro  s all to lar e ere a ro e . i e of t e  are ro ce  si  soli - ase tec olo , 
t ere  s o i  o ce a ai  t at t is si le t efficie t a roac  e elo e   t e o el a reate 
r ce errifiel  is a ote t tool for r  isco er  [10].  
lt o  ca cer r s recei e  t e ost a ro als i  2017, it is i orta t to i li t t at 
se eral r s a ai st i fectio s iseases ere also a t orize . 
e o t ts fro  2017 i icate t at totall  s t etic (fro  t e i ea) s all olec les are losi  
ro  a ai st iolo ics, io olec les, a  ot er olec les i s ire   at ral ro cts. o e er, 
all r s, re ar less of t e c e ical s ecies i ol e , ill e see  to ac ie e t eir issio  if t e  are 
a le to relie e s fferi . ere is o e t at t e fi res for 2018 ill excee  t ose of 2017.  
c o le g e ts: he ork perfor e  by the authors is fun e  by the ational esearch Foun ation ( F) 
an  the niversity of a ulu- atal. 
t or o tri tio s: oth authors rote the paper. 
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, l
As entioned in the introduction, in “Drugs to the arket” it is very difficult to interpret trends
and thus ake forecasts for the co ing years. However, if the approval of seven antibodies and three
oligonucleotides were the most notable achievements in recent years, in 2017 the number of antibodies
increased to nine and, more importantly, one ADC was approved. These figures serve to support the
notion that these molecules will become the “Drugs of the Future” for the treatment of hitherto intractable
diseases. It is to be hoped that production methods will evolve to be more cost effective and antibody-based
drugs will become affordable for much of the population. This comment also applies to the production of
combination drugs to treat hepatitis C, which are currently unaffordable for a large number of patients.
The strength of the privileged structures in the drug discovery process has been clearly highlighted
by the approval of six drugs containing 2-amine-pyrimidine moiety, one with a triazine structure,
and two with a nitroimidazole.
In 2017, the TIDES section was dominated by peptides. In this regard, six peptides ranging in
size from small to large were approved. Five of them are produced using solid-phase technology,
thereby showing once again that this simple but efficient approach developed by the Nobel Laureate
Bruce Merrifield is a potent tool for drug discovery [10].
Although cancer drugs received the most approvals in 2017, it is important to highlight that
several drugs against infectious diseases were also authorized.
The outputs from 2017 indicate that totally synthetic (from the idea) small molecules are losing
ground against biologics, biomolecules, and other molecules inspired by natural products. However,
all drugs, regardless of the chemical species involved, will be seen to achieve their mission if they are
able to relieve suffering. There is hope that the figures for 2018 will exceed those of 2017.
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